Macular edema (retinal fluid) secondary to inflammation (MESI)
KODKodiak Sciences Inc.Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for KSI-101 in Macular edema (retinal fluid) secondary to inflammation (MESI). The expected timing is based on the latest available company guidance and may change.
APEX, PINNACLE, and PEAK studies. 8/14/24- Enrollment ongoing 3/27/25- Ph2b/3 trial initiated. 11/5/25- APEX follow up data reported. PEAK & PINNACLE ongoing enrollment. Present 24wk data on February 7, 2026. 11/13/25:- APEX enrollment complete; 24wk data February 7, 2026. PEAK topline Q4 2026; PINNACLE Q1 2027. 02/04/26:- APEX Phase 1b MESI end-of-study results February 7, 2026; PEAK topline Q4 2026; PINNACLE topline Q2 2027. 03/31/26:- Final APEX Ph1b MESI data showed rapid, durable vision and retinal improvements; PEAK Q4 2026, PINNACLE Q2 2027 unchanged. 05/01/26:- APEX Week 24 and Asian cohort MESI data to be presented at AUS May 2 and ARVO May 4-6, 2026. 05/07/26:- APEX Phase 1b data detailed strong visual gains and retinal dryness; PEAK Q4 2026, PINNACLE Q2 2027 reiterated. 08/06/26:- PEAK cohort 1 (300 patients) enrollment complete; PEAK topline December 2026; Pivotal Analysis 2 topline Q2 2027. 08/13/26:- PEAK Pivotal Analysis 1 topline data will be reported in December 2026. Pivotal Analysis 2 topline data will be reported in Q2 2027.
Verification
Confirm timing and program details against the company announcement or filing.